Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 platform basket study of risankizumab-based advanced therapies in moderate to severe Crohn's disease and ulcerative colitis
jRCT2061260080Phase 2Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2 trial of risankizumab, livmoniplimab, FG-M701, risankizumab + trosunilimab and ABBV-7066 in Crohn's disease and autoimmune colitis (21 arms), sponsored by AbbVie Inc. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
risankizumablivmoniplimabFG-M701risankizumab + trosunilimabABBV-7066
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on jRCT2061260080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061260080.